Over a third of low-grade (1-2) toxicities are considered "life-changing" by patients. CTCAE grades were designed for physician decision-making (e.g., is it safe to give the next dose?), not to capture the true, long-term impact on a patient's quality of life.

Even when desmoid tumor patients seem to tolerate niragacestat well, they often report a surprising improvement in well-being after discontinuing the drug. This reveals a subtle, cumulative quality-of-life impact from low-grade toxicities that may not be fully appreciated by patients or clinicians during active treatment.

A patient's reminder that even clinically-graded "mild" side effects like grade 2 diarrhea can be debilitating highlights a disconnect between clinical assessment and patient experience. This underscores the need for oncologists to consider the real-world impact of toxicities, like the ability to leave the house, when choosing a treatment regimen.

Radioligand therapy has a unique toxicity profile, described as 'the gift that keeps on giving,' where side effects can worsen even after the treatment course is complete. This contrasts with chemotherapy like docetaxel, where a patient's quality of life often rebounds and improves once the drug is stopped.

Current Quality of Life (QoL) assessments in cancer trials fail to capture severe, long-term toxicities. They are designed for short-term effects and data collection often ceases after a patient experiences a life-changing adverse event, thus painting an inaccurately rosy picture of a drug's tolerability.

The structured support from nurses and doctors abruptly stops after major treatments like chemotherapy conclude. This creates a feeling of being orphaned, as patients lose their primary point of contact for ongoing side effects and fears, highlighting a critical gap in long-term survivorship care.

Oncology research is moving beyond standard quality-of-life metrics to study 'decision regret' and toxicity perception after adjuvant therapy is completed. This novel approach better captures the long-term psychological impact on patients, whose perspectives often change dramatically months or years after their initial treatment decision.

Quality of Life data collected only during clinic visits fails to capture the patient's experience during their "off" weeks, which is often when they feel the worst. Accurate QoL assessment requires remote, high-frequency data collection to get a true picture of the treatment burden over time.

Current quality of life assessments in trials are inadequate for immunotherapy. They fail to track life-altering toxicities that persist long after patients stop treatment, as data collection often ceases. This systemic flaw dilutes the true patient burden and calls for new methods to measure long-term, post-treatment quality of life.